Stock Track | Mirum Pharmaceuticals Plummets 11.13% Intraday Amid Mixed Analyst Sentiment and RBC Price Target Cut

Stock Track02-26

Mirum Pharmaceuticals, Inc. (MIRM) experienced a significant intraday plummet of 11.13% on Thursday, extending losses from pre-market trading.

The sharp decline follows mixed analyst sentiment toward the healthcare company. While several firms including Stifel, Raymond James, and Morgan Stanley raised their price targets on Mirum Pharmaceuticals, RBC Capital Markets lowered its target to $128 from $130 while maintaining an Outperform rating. This downward adjustment from RBC appears to have contributed to investor concerns despite the overall positive outlook from other analysts.

According to FactSet data, Mirum Pharmaceuticals maintains an average buy rating with a mean price target of $122.36. The conflicting signals from analysts, particularly RBC's reduced target, created uncertainty that likely triggered the substantial selling pressure during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148827858?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148827858","market":"sg","top_or_hot":-1,"title":"Stock Track | Mirum Pharmaceuticals Plummets 11.13% Intraday Amid Mixed Analyst Sentiment and RBC Price Target Cut","media":"Stock Track","content":"<p>Mirum Pharmaceuticals, Inc. (MIRM) experienced a significant intraday plummet of 11.13% on Thursday, extending losses from pre-market trading.</p><p>The sharp decline follows mixed analyst sentiment toward the healthcare company. While several firms including Stifel, Raymond James, and Morgan Stanley raised their price targets on Mirum Pharmaceuticals, RBC Capital Markets lowered its target to $128 from $130 while maintaining an Outperform rating. This downward adjustment from RBC appears to have contributed to investor concerns despite the overall positive outlook from other analysts.</p><p>According to FactSet data, Mirum Pharmaceuticals maintains an average buy rating with a mean price target of $122.36. The conflicting signals from analysts, particularly RBC's reduced target, created uncertainty that likely triggered the substantial selling pressure during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mirum Pharmaceuticals Plummets 11.13% Intraday Amid Mixed Analyst Sentiment and RBC Price Target Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mirum Pharmaceuticals Plummets 11.13% Intraday Amid Mixed Analyst Sentiment and RBC Price Target Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mirum Pharmaceuticals, Inc. (MIRM) experienced a significant intraday plummet of 11.13% on Thursday, extending losses from pre-market trading.</p><p>The sharp decline follows mixed analyst sentiment toward the healthcare company. While several firms including Stifel, Raymond James, and Morgan Stanley raised their price targets on Mirum Pharmaceuticals, RBC Capital Markets lowered its target to $128 from $130 while maintaining an Outperform rating. This downward adjustment from RBC appears to have contributed to investor concerns despite the overall positive outlook from other analysts.</p><p>According to FactSet data, Mirum Pharmaceuticals maintains an average buy rating with a mean price target of $122.36. The conflicting signals from analysts, particularly RBC's reduced target, created uncertainty that likely triggered the substantial selling pressure during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1148827858","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148827858","pubTimestamp":1772119052,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mirum Pharmaceuticals, Inc. (MIRM) experienced a significant intraday plummet of 11.13% on Thursday, extending losses from pre-market trading.The sharp decline follows mixed analyst sentiment toward...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc."},"translate_title":"个股追踪|Mirum Pharmaceuticals盘中暴跌11.13%，分析师情绪不一，RBC目标价下调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1},"content_text":"Mirum Pharmaceuticals, Inc. (MIRM) experienced a significant intraday plummet of 11.13% on Thursday, extending losses from pre-market trading.The sharp decline follows mixed analyst sentiment toward the healthcare company. While several firms including Stifel, Raymond James, and Morgan Stanley raised their price targets on Mirum Pharmaceuticals, RBC Capital Markets lowered its target to $128 from $130 while maintaining an Outperform rating. This downward adjustment from RBC appears to have contributed to investor concerns despite the overall positive outlook from other analysts.According to FactSet data, Mirum Pharmaceuticals maintains an average buy rating with a mean price target of $122.36. The conflicting signals from analysts, particularly RBC's reduced target, created uncertainty that likely triggered the substantial selling pressure during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148827858","isCrawlerRequest":true}